{"entity":{"id":"nct05830123","kind":"trial","name":"ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas","aka":[],"tldr":"A phase 2 trial of HS-20093 in osteosarcoma, run by Hansoh BioMedical R&D Company, now recruiting.","summary":"ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas is a phase 2 interventional study registered as NCT05830123 by Hansoh BioMedical R&D Company, with 170 participants planned, started 2023-06-08 and due to reach its primary completion in 2025-12-31. Interventions recorded: HS-20093. Conditions listed: Osteosarcoma, Sarcoma. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05830123","url":"https://clinicaltrials.gov/study/NCT05830123"}],"tags":["ctgov-ingest"],"related":[],"cancers":["osteosarcoma"],"sections":[],"technologies":[],"targets":[],"drugs":["hs-20093"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05830123","phase":"2","setting":"ARTEMIS-002: A Phase 2, Multicenter, Open-label Study of Intravenous Administration of HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas","sponsor":"Hansoh BioMedical R&D Company","enrolled":170,"outcomes":[]},"route":"/trials/nct05830123/","neighbours":{"cancer":[{"id":"osteosarcoma","kind":"cancer","name":"Osteosarcoma","route":"/cancers/osteosarcoma/"}],"drug":[{"id":"hs-20093","kind":"drug","name":"HS-20093","route":"/drugs/hs-20093/"}]}}